Phath­om's old Take­da drug bests Pre­vacid in a PhI­II GI tri­al. Next stop? The FDA

There’s no time for rest in bio­phar­ma — at least not at Phath­om Phar­ma­ceu­ti­cals. Just over a month af­ter sub­mit­ting two NDAs for its lead acid-fight­er vono­prazan, the biotech is al­ready lin­ing up a third, and col­lect­ing an ex­tra $50 mil­lion to push things along.

Vono­prazan met its pri­ma­ry non-in­fe­ri­or­i­ty end­points in a Phase III study com­par­ing it to stan­dard-of-care Pre­vacid in a type of gas­troe­sophageal re­flux dis­ease (GERD) called ero­sive esophagi­tis (EE). It al­so proved su­pe­ri­or to the pop­u­lar heart­burn drug by mul­ti­ple mea­sures, in­clud­ing heal­ing rate and main­te­nance of heal­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER